MedTrace Logo

PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow

NCT00380263 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2008-05-30

No results posted yet for this study

Summary

To investigate headache score and accompanying symptoms during and after infusion of PACAP38 i migraine patients

Conditions

  • Migraine Without Aura

Interventions

DRUG

PACAP38

10 pmol/kg/min given one time

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Principal Investigators

  • Henrik Schytz, MD · Danish Headache Center

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00380263 on ClinicalTrials.gov